BICO Group AB (publ) (STO:BICO)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 1.38B |
| Revenue (ttm) | 1.50B |
| Net Income (ttm) | -1.09B |
| Shares Out | 70.57M |
| EPS (ttm) | -15.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 293,465 |
| Average Volume | 291,098 |
| Open | 19.68 |
| Previous Close | 19.62 |
| Day's Range | 18.80 - 19.68 |
| 52-Week Range | 15.30 - 42.46 |
| Beta | 2.52 |
| RSI | 51.67 |
| Earnings Date | Apr 29, 2026 |
About BICO Group AB
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and application... [Read more]
Financial Performance
In 2025, BICO Group AB's revenue was 1.50 billion, a decrease of -13.32% compared to the previous year's 1.73 billion. Losses were -1.09 billion, 19698.2% more than in 2024.
Financial StatementsNews
BICO Group AB Earnings Call Transcript: Q4 2025
2025 ended with strong Lab Automation growth and improved cash position, despite overall negative organic sales growth and challenging market conditions. New capital was raised to support future growth, and product launches like GoSimple received strong interest.
BICO Group AB Earnings Call Transcript: Q3 2025
Q3 2025 delivered 12% organic sales growth and improved margins, driven by strong lab automation demand and major commercial wins. Divestments strengthened the cash position, while impairments impacted EBIT but not cash flow. Positive outlook with stable R&D and cost control.
BICO Group AB Earnings Call Transcript: Q2 2025
Q2 2025 saw negative organic growth and profitability challenges, mainly due to project delays in Lab Automation, while Life Science Solutions delivered flat sales. The divestment of MatTek and Visikol strengthened the balance sheet, and operational improvements are underway to address project execution and margin pressures.
BICO Group AB Earnings Call Transcript: Q1 2025
Q1 2025 saw a 19% organic sales decline but stable adjusted EBITDA, with bioprinting and life science solutions showing growth. The divestment of MatTek and Visikol will move the group to a net cash position in Q2 2025, supporting a strategic focus on lab automation and pharma/biotech customers.
BICO Group AB Earnings Call Transcript: Q4 2024
Q4 2024 saw stable sales, significant margin improvement, and strong cash flow, with all business areas achieving double-digit EBITDA margins. The company divested non-core assets, reduced debt, and is well-positioned for gradual market recovery, focusing on commercial and R&D initiatives.
BICO Group AB Earnings Call Transcript: Q3 2024
Q3 2024 saw weak instrument sales and a net loss, but all business areas remained profitable with improved gross margin. Key actions included divesting Nanoscribe, repurchasing convertible bonds, and rightsizing CELLINK, with a continued focus on operational excellence and debt reduction.
BICO Group AB Transcript: CMD 2024
BICO unveiled its BICO 2.0 strategy, focusing on lab automation, integrated workflows, and recurring revenue, with new business areas and a realigned executive team. Lab Automation sales surged 40% YoY, and financial targets were reiterated despite market headwinds. AI-driven automation and strategic partnerships are central to future growth.
BICO Group AB Earnings Call Transcript: Q2 2024
Q2 2024 saw SEK 534 million in sales with -2% organic growth, all segments EBITDA positive, and improved gross margin. Market remains volatile, especially in Asia, but cost control and strategic hires support ongoing transformation.
BICO Group AB Earnings Call Transcript: Q1 2024
BICO Group AB Earnings Call Transcript: Q4 2023
BICO Group AB Earnings Call Transcript: Q3 2023
BICO Group AB Transcript: Status Update
BICO Group AB Earnings Call Transcript: Q2 2023
BICO Group AB Earnings Call Transcript: Q1 2023
BICO Group AB Earnings Call Transcript: Q4 2022
BICO Group AB Transcript: CMD 2022
BICO Group AB Earnings Call Transcript: Q3 2022
BICO Group AB Earnings Call Transcript: Q2 2022
BICO Group AB Earnings Call Transcript: Q2 2022
BICO Group AB Earnings Call Transcript: Q1 2022
BICO Group AB Earnings Call Transcript: Q4 2021
4 X-Factors That Could Send BICO's Stock Soaring
The outlook is bright for this pioneering company.
